JP7893751B2 - ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法 - Google Patents

ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法

Info

Publication number
JP7893751B2
JP7893751B2 JP2022566323A JP2022566323A JP7893751B2 JP 7893751 B2 JP7893751 B2 JP 7893751B2 JP 2022566323 A JP2022566323 A JP 2022566323A JP 2022566323 A JP2022566323 A JP 2022566323A JP 7893751 B2 JP7893751 B2 JP 7893751B2
Authority
JP
Japan
Prior art keywords
clofazimine
dry powder
pharmaceutical composition
composition according
inhalable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022566323A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524064A (ja
JP2023524064A5 (enExample
Inventor
ホフマン トーマス
ウーファ ステファン
ジェイ ジュニア フリーマン ジョン
Original Assignee
マンカインド コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マンカインド コーポレイション filed Critical マンカインド コーポレイション
Publication of JP2023524064A publication Critical patent/JP2023524064A/ja
Publication of JP2023524064A5 publication Critical patent/JP2023524064A5/ja
Application granted granted Critical
Publication of JP7893751B2 publication Critical patent/JP7893751B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2022566323A 2020-05-01 2021-04-30 ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法 Active JP7893751B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063018677P 2020-05-01 2020-05-01
US63/018,677 2020-05-01
PCT/US2021/030155 WO2021222740A1 (en) 2020-05-01 2021-04-30 Clofazimine composition and method for the treatment or prophylaxis of viral infections

Publications (3)

Publication Number Publication Date
JP2023524064A JP2023524064A (ja) 2023-06-08
JP2023524064A5 JP2023524064A5 (enExample) 2024-05-09
JP7893751B2 true JP7893751B2 (ja) 2026-07-22

Family

ID=78332269

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022566323A Active JP7893751B2 (ja) 2020-05-01 2021-04-30 ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法

Country Status (9)

Country Link
US (1) US20230248722A1 (enExample)
EP (1) EP4142691A4 (enExample)
JP (1) JP7893751B2 (enExample)
KR (1) KR20230005937A (enExample)
CN (1) CN115666510A (enExample)
AU (1) AU2021263580B2 (enExample)
BR (1) BR112022022081A2 (enExample)
CA (1) CA3177438A1 (enExample)
WO (1) WO2021222740A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023102363A1 (en) * 2021-11-30 2023-06-08 Mannkind Corporation Formulation and method for topical treatment of mycobacterium ulcerans in buruli ulcers
JP2025529312A (ja) * 2022-09-06 2025-09-04 マンカインド コーポレイション 非結核性抗酸菌症を処置するための方法
WO2025091042A1 (en) * 2023-10-27 2025-05-01 Mannkind Corporation Methods for treating non-tuberculous mycobacterial infection

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016515522A (ja) 2013-03-15 2016-05-30 マンカインド コーポレイション 微結晶性ジケトピペラジン組成物および方法
JP2017531673A (ja) 2014-10-24 2017-10-26 レッド ヒル バイオファーマ リミテッドＲｅｄＨｉｌｌ Ｂｉｏｐｈａｒｍａ Ｌｔｄ． １本鎖ｒｎａウイルス複製を阻害するための治療
CN108853106A (zh) 2017-05-09 2018-11-23 中国食品药品检定研究院 亚胺吩嗪类化合物作为狂犬病病毒抑制剂的用途
WO2019070693A1 (en) 2017-10-02 2019-04-11 Board Of Regents, The University Of Texas System COMPOSITION FOR INHALING CLOFAZIMINE AND METHODS OF USE
WO2019110099A1 (en) 2017-12-06 2019-06-13 Qrumpharma Inc. Inhalable clofazimine formulation
WO2020040818A1 (en) 2018-08-23 2020-02-27 Qrumpharma Inc. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071127B2 (en) * 2006-10-24 2011-12-06 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
MY155524A (en) 2008-06-13 2015-10-30 Mannkind Corp A dry powder inhaler and system for drug delivery
KR101822208B1 (ko) * 2009-11-02 2018-01-25 맨카인드 코포레이션 약학적 조성물을 극저온 과립화하는 장치 및 방법
RU2016143590A (ru) * 2014-04-08 2018-05-11 Арадайм Корпорейшн Липосомальные композиции ципрофлоксацина, обладающие активностью против нетуберкулезных микробактерий
WO2016123530A1 (en) * 2015-01-30 2016-08-04 The Regents Of The University Of Michigan Compositions and methods for delivering pharmaceutical agents

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016515522A (ja) 2013-03-15 2016-05-30 マンカインド コーポレイション 微結晶性ジケトピペラジン組成物および方法
JP2017531673A (ja) 2014-10-24 2017-10-26 レッド ヒル バイオファーマ リミテッドＲｅｄＨｉｌｌ Ｂｉｏｐｈａｒｍａ Ｌｔｄ． １本鎖ｒｎａウイルス複製を阻害するための治療
CN108853106A (zh) 2017-05-09 2018-11-23 中国食品药品检定研究院 亚胺吩嗪类化合物作为狂犬病病毒抑制剂的用途
WO2019070693A1 (en) 2017-10-02 2019-04-11 Board Of Regents, The University Of Texas System COMPOSITION FOR INHALING CLOFAZIMINE AND METHODS OF USE
WO2019110099A1 (en) 2017-12-06 2019-06-13 Qrumpharma Inc. Inhalable clofazimine formulation
WO2020040818A1 (en) 2018-08-23 2020-02-27 Qrumpharma Inc. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Banaschewski Brandon，Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections，Journal of Cystic Fibrosis，Vol.18,No.5，2019年05月，ＵＲＬ，https://doi.org/10.1016/j.jcf.2019.05.013

Also Published As

Publication number Publication date
CA3177438A1 (en) 2021-11-04
AU2021263580A1 (en) 2022-11-24
US20230248722A1 (en) 2023-08-10
JP2023524064A (ja) 2023-06-08
CN115666510A (zh) 2023-01-31
BR112022022081A2 (pt) 2022-12-13
WO2021222740A1 (en) 2021-11-04
AU2021263580B2 (en) 2026-08-06
EP4142691A4 (en) 2024-05-15
EP4142691A1 (en) 2023-03-08
KR20230005937A (ko) 2023-01-10

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240424

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251008

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260420

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260609

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260709

R150 Certificate of patent or registration of utility model

Ref document number: 7893751

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150